Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colchicine + clarithromycin is a combination of two drugs—colchicine, an anti-inflammatory agent used mainly for gout and familial Mediterranean fever, and clarithromycin, a macrolide antibiotic frequently used for bacterial infections. When used together, clarithromycin (a strong inhibitor of CYP3A4 and P-glycoprotein) substantially increases colchicine plasma levels, dramatically raising the risk of life-threatening colchicine toxicity. Documented outcomes include fatal multi-organ failure, myopathy, rhabdomyolysis, pancytopenia, and bone marrow suppression. Due to these mechanisms and strong evidence from clinical and pharmacovigilance databases, concurrent administration is generally contraindicated[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colchicine + clarithromycin.